Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Sales of Investments
Cash received from selling or redeeming investments.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $54.65M fell 64.5% year over year, behind the -52.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at -3.7% a year.
Context
- Sales of investments amounted to 1040788.9% of revenue in FY2025, up 140885.6 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -64.5% toward the trailing-twelve-month pace of -52.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 374.68M USD
- Year-over-year change
- -31.7%
- 4-year CAGR
- -11.7%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 374.68M | -31.7% |
| FY2024 | 2024-12-31 | 548.94M | -17.3% |
| FY2023 | 2023-12-31 | 663.61M | +58.4% |
| FY2022 | 2022-12-31 | 419.05M | -32.1% |
| FY2021 | 2021-12-31 | 617.4M | — |
Sales of Investments vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -52.0% is the 8th highest of 9, against a peer median of -13.2%.
- Sales of investments amounts to 887777.4% of revenue for LYEL, versus a peer median of 449.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $385.18M USD | -2.0% | +109.8% | — | |
| LTM Mar 2026 | $275.21M USD | -52.0% | -3.7% | 887777.4% | |
| LTM Mar 2026 | $249.82M USD | -36.1% | -13.3% | — | |
| LTM Mar 2026 | $196.48M USD | -13.0% | -6.6% | 91.4% | |
| LTM Mar 2026 | $146M USD | -24.5% | +62.7% | — | |
| LTM Mar 2026 | $101.74M USD | — | — | 11040.3% | |
| LTM Mar 2026 | $100.96M USD | +104.0% | +26.0% | — | |
| LTM Mar 2026 | $82.51M USD | -64.2% | -31.5% | 213.2% | |
| LTM Mar 2026 | $65M USD | -13.3% | +11.8% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $32.28M USD | +25.4% | — | 403500.0% |
| LTM Dec 2025 | CHF 16.05M CHF | — | — | 449.1% | |
| Peer median (excluding LYEL) | — | -13.2% | +11.8% | 449.1% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Depreciation & Amortization | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M |
| Deferred Income Tax | 39.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 62.2M | 0 | 47.08M | 33.14M | 41.83M |
| Change in Working Capital | 4.02M | (82.02M) | 3.42M | (3.12M) | (9.89M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 91K | 667K | 1.46M | (3.23M) | (2.34M) |
| Other Working Capital | 3.92M | (82.68M) | 1.96M | 114K | (7.56M) |
| Other Non-Cash Items | 4.62M | 79.11M | 183K | 130.95M | 80.95M |
| Operating Cash Flow | (126.25M) | (169.56M) | (163.69M) | (162.39M) | (150.02M) |
| Capital Expenditures | (65.5M) | (24.28M) | (2.69M) | (464K) | (780K) |
| Acquisitions (Net) | 673.47M | 0 | 0 | (31.35M) | (41.2M) |
| Purchases of Investments | (673.47M) | (406.32M) | (476.88M) | (394.71M) | (259.71M) |
| Sales of Investments | 617.4M | 419.05M | 663.61M | 548.94M | 374.68M |
| Other Investing Activities | (673.47M) | 0 | 0 | 0 | (18.9M) |
| Investing Cash Flow | (121.57M) | (11.54M) | 184.05M | 122.42M | 54.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.44M | (461K) | (457K) | (76K) | (1K) |
| Financing Cash Flow | 401.24M | 10.64M | 1.74M | 1.33M | 50.41M |
| Effect of Forex Changes | 0 | 186K | (4K) | 0 | 0 |
| Net Change in Cash | 153.42M | (170.27M) | 22.09M | (38.64M) | (45.52M) |
| Free Cash Flow | (191.75M) | (193.83M) | (166.38M) | (162.86M) | (150.8M) |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.